UroGen Share Price

UroGen Share Price

NASDAQ: URGN | Small Cap | Healthcare
$27.64
-$4.00 (-12.65%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

UroGen Stock Performance

Open
$31.15
Prev. Close
$31.65
Circuit Range
N/A
Day Range
$27.57 - $31.86
Year Range
$16.61 - $50.76
Volume
1,53,975
Average Traded
$30.17

UroGen Share Price Today

As of 22 November 2026, UroGen Pharma Ltd.'s share price is $27.64. The stock opened at $31.15, compared to its previous close of $31.65. During today's trading session, UroGen Pharma Ltd.'s share price traded between $27.57 and $31.86, with an average price of $29.72. Over the past 52 weeks, the stock has recorded a high of $50.76 and a low of $16.61. In terms of performance, UroGen Pharma Ltd.'s share price has declined by 1.69% over the last six months and is down 3.88% on a year-on-year basis.

UroGen Share Price Chart

Line chart of the UroGen price trend over the selected period. The price fell overall, ranging from 27.64 to 31.88, ending at 27.64.
$27.57$31.86
L
Show Current Price
H

UroGen Stock Fundamentals & Key Indicators

Market Cap
$1.33B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.34
Revenue (TTM)
$109.79B
Return On Equity (TTM)
52.51%
Profit Margin
-139.80%
Debt to Equity
-1.54
Quarterly Earnings Growth YoY
94.46%

UroGen Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$37.84$50.96$72.46$89.00
Net Profit-$26.36-$23.57-$14.35-$1.46
Net Profit Margin-69.66%-46.25%-19.80%-1.64%
Income ChangeN/A10.58%39.12%89.83%

UroGen Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$64.36$82.71$90.40$109.79
Net Profit-$109.78-$102.24-$126.87-$153.49
Net Profit Margin-170.57%-123.61%-140.34%-139.80%
Income ChangeN/A6.87%-24.09%-20.98%

UroGen Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets14.439.589.136.71
Current Assets186.02276.14169.19128.91
Total Assets200.46285.71178.31135.62
Non Current Liabilities259.51248.57212.31201.06
Current Liabilities46.4245.9531.2123.92
Total Liabilities305.93294.51243.52224.98
Shareholders' Equity-105.47-8.8-65.21-89.36

UroGen Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-162.44-96.77-76.38-87.56
Investing61.56-20.61-0.951.06
Financing39.92194.62116.9397.13

About UroGen

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

UroGen Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$33.17
$27.72
-15.20%
Oct 2026
$40.89
$32.69
-19.72%
Sep 2026
$42.98
$40.72
-10.59%
Aug 2026
$37.41
$45.55
+19.29%
Jul 2026
$37.39
$38.18
+3.75%
Jun 2026
$27.70
$36.80
+30.87%
May 2026
$23.93
$28.12
+17.95%
Apr 2026
$18.27
$23.84
+32.59%
Mar 2026
$21.39
$17.98
-17.20%
Feb 2026
$19.42
$21.71
+10.71%
Jan 2026
$23.73
$19.61
-16.48%
Dec 2025
$28.45
$23.48
-18.34%

UroGen Share Price FAQs